

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202441096248 A

(19) INDIA

(22) Date of filing of Application :05/12/2024

(43) Publication Date : 13/12/2024

(54) Title of the invention : Method of synthesizing Spiro-Pyrrolizidine-Benzyloxy hybrid with doxorubicin to enhanced anticancer activity

(51) International classification :A61P0035000000, A61K0031704000, C07D0487040000, C12N0005160000, A61P0035020000
(86) International Application No :NA
Filing Date :NA
(87) International Publication No : NA
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA

(71)Name of Applicant :
1)ANNAMALAI UNIVERSITY
Address of Applicant :Annamalai Nagar, Chidambaram - 608002 Tamilnadu India -----
Name of Applicant : NA
Address of Applicant : NA
(72)Name of Inventor :
1)UTHIRAPATHI RAJAPANDIYAN
Address of Applicant :Department of Chemistry, Annamalai University, Annamalai Nagar Chidambaram - 608002 Chidambaram -----
2)H. MANIKANDAN
Address of Applicant :Department of Chemistry, Annamalai University Annamalai Nagar Chidambaram - 608002 Chidambaram -----
3)M.RAJ KUMAR
Address of Applicant :Department of Chemistry, Annamalai University Annamalai Nagar Chidambaram - 608002 Chidambaram -----
4)U. KALAIVANAN
Address of Applicant :Department of Chemistry, Annamalai University Annamalai Nagar, Chidambaram - 608002 Chidambaram -----
5)V. RAJATHI
Address of Applicant :Department of Zoology Government Arts College, C. Mutlur Chidambaram - 608102 Chidambaram -----
6)K. SIVAKUMAR
Address of Applicant :Department of Chemistry Sri Chandrasekharendra Saraswathi Viswa Mahavidyalaya Kanchipuram - 631 561 Kanchipuram -----

(57) Abstract :
ABSTRACT Method of synthesizing spiro-pyrrolizidine-benzyloxy hybrid with doxorubicin to enhanced anticancer activity. The product obtained is spiro-pyrrolizidine-benzyloxy hybrid named as 1'-benzoyl-2'-(4-(benzyloxy)phenyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one. Upon evaluating the MTT assay for anticancer activity against the MDA-MB-231 cell line the compound RP1 exhibited strong inhibition of cancer cells. The combination dose consisting of mixture of 1'-benzoyl-2'-(4-(benzyloxy)phenyl)-1',2',5',6',7',7a'-hexahydrospiro[indoline-3,3'-pyrrolizin]-2-one and Doxorubicin in the ratio 80:20 exhibits strong anticancer effect .

No. of Pages : 29 No. of Claims : 1